New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine;   - film coated tablet - 1 mg - active: trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine;   - film coated tablet - 2 mg - active: trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine;   - film coated tablet - 5 mg - active: trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine; tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine - film coated tablet - 10 mg - active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax red spectraspray acsl0673 erythrosine gelatin hypromellose magnesium stearate maize starch propylene glycol shellac sucrose active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax erythrosine gelatin magnesium stearate maize starch opadry red 06h250000 sucrose - parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. it is not recommended for use in mild depressive states resulting from temporary situational difficulties.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - fentanyl citrate 78.5 µg/ml equivalent to 50 µg/ml fentanyl - solution for injection - 50 mcg/ml - active: fentanyl citrate 78.5 µg/ml equivalent to 50 µg/ml fentanyl excipient: sodium chloride sodium hydroxide water for injection - fentanyl injection is indicated for: · analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises; · use as a narcotic analgesic supplement in general and regional anaesthesia; · administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranexamic acid 500mg - film coated tablet - 500 mg - active: tranexamic acid 500mg excipient: basic butylated methacrylate copolymer colloidal silicon dioxide croscarmellose sodium isopropyl alcohol macrogol 8000 magnesium stearate   microcrystalline cellulose povidone purified talc   purified water titanium dioxide vanillin - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: -prostatectomy and bladder surgery -menorrhagia -epistaxis -conisation of the cervix - management of dental extraction in patients with coagulopathies - ulcerative colitis - haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma) -gastrointestinal haemorrhage general fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery: - in obstetrical complications such as abruptio placentae and post-partum haemorrhage - in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase hereditary angioneurotic oedema. for the reduction of peri– and post-operative blood loss and the need for blood transfusion in adult patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. for the reduction of peri- and post-operative blood loss and the need for blood transfusion in paediatric patients undergoing cardiac surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.05mg (anhydrous) - tablet - 0.05 mg - active: levothyroxine sodium 0.05mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.1mg (anhydrous) - tablet - 0.1 mg - active: levothyroxine sodium 0.1mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - prucalopride succinate 1.321mg equivalent to 1 mg prucalopride - film coated tablet - 1 mg - active: prucalopride succinate 1.321mg equivalent to 1 mg prucalopride excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 33g28707 purified water - treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - prucalopride succinate 2.642mg equivalent to 2 mg prucalopride - film coated tablet - 2 mg - active: prucalopride succinate 2.642mg equivalent to 2 mg prucalopride excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose opadry pink 33g34847 purified water - treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.